ArticleElectrophoresis2013
Targeted metabolic profiling of hepatocellular carcinoma and hepatitis C using LC-MS/MS.
Article in Electrophoresis, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Systematic review of metabolomic profiles linked to liver cancer.Journal of liver cancer · 2026Article
- Review
- Differences in Prediagnostic Serum Metabolomic and Lipidomic Profiles Between Cirrhosis Patients with and without Incident Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2024Article
- Molecular and Metabolic Phenotyping of Hepatocellular Carcinoma for Biomarker Discovery: A Meta-Analysis.Metabolites · 2023Article
- Rewiring of the Host Cell Metabolome and Lipidome during Lytic Gammaherpesvirus Infection Is Essential for Infectious-Virus Production.Journal of virology · 2023Article
- Discriminatory Changes in Circulating Metabolites as a Predictor of Hepatocellular Cancer in Patients with Metabolic (Dysfunction) Associated Fatty Liver Disease.Liver cancer · 2023Article
- Metabolomics in viral hepatitis: advances and review.Frontiers in cellular and infection microbiology · 2023Review
- Metabolic Analysis of Nucleosides/Bases in the Urine and Serum of Patients with Alcohol-Associated Liver Disease.Metabolites · 2022Article
- Spatial metabolomics on liver cirrhosis to hepatocellular carcinoma progression.Cancer cell international · 2022Article
- Microbiome-Based Metabolic Therapeutic Approaches in Alcoholic Liver Disease.International journal of molecular sciences · 2022Review
- Proteomics-based identification of TMED9 is linked to vascular invasion and poor prognoses in patients with hepatocellular carcinoma.Journal of biomedical science · 2021Article
- Advances in Multi-Omics Applications in HBV-Associated Hepatocellular Carcinoma.Frontiers in medicine · 2021Review
- Comprehensive Dipeptide Analysis Revealed Cancer-Specific Profile in the Liver of Patients with Hepatocellular Carcinoma and Hepatitis.Metabolites · 2020Article
- Distinguishing NASH Histological Severity Using a Multiplatform Metabolomics Approach.Metabolites · 2020Article
- Article
- Hydralazine targets cAMP-dependent protein kinase leading to sirtuin1/5 activation and lifespan extension in C. elegans.Nature communications · 2019Article
- Function, Detection and Alteration of Acylcarnitine Metabolism in Hepatocellular Carcinoma.Metabolites · 2019Review
- Assessing the Effectiveness of Direct Data Merging Strategy in Long-Term and Large-Scale Pharmacometabonomics.Frontiers in pharmacology · 2019Article
- Metabolomics: From liver chiromancy to personalized precision medicine in advanced chronic liver disease.World journal of hepatology · 2018Review
- Differential diagnosis between hepatocellular carcinoma and cirrhosis by serum amino acids and acylcarnitines.International journal of clinical and experimental pathology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Hepatitis C virus (HCV) infection of the liver is a global health problem and a major risk factor for the development of hepatocellular carcinoma (HCC). Sensitive methods are needed for the improved and earlier detection of HCC, which would provide better therapy options. Metabolic profiling of the high-risk population (HCV patients) and those with HCC provides insights into the process of liver carcinogenesis and possible biomarkers for earlier cancer detection. Seventy-three blood metabolites were quantitatively profiled in HCC (n = 30) and cirrhotic HCV (n = 22) patients using a targeted approach based on LC-MS/MS. Sixteen of 73 targeted metabolites differed significantly (p < 0.05) and their levels varied up to a factor of 3.3 between HCC and HCV. Four of these 16 metabolites (methionine, 5-hydroxymethyl-2'-deoxyuridine, N2,N2-dimethylguanosine, and uric acid) that showed the lowest p values were used to develop and internally validate a classification model using partial least squares discriminant analysis. The model exhibited high classification accuracy for distinguishing the two groups with sensitivity, specificity, and area under the receiver operating characteristic curve of 97%, 95%, and 0.98, respectively. A number of perturbed metabolic pathways, including amino acid, purine, and nucleotide metabolism, were identified based on the 16 biomarker candidates. These results provide a promising methodology to distinguish cirrhotic HCV patients, who are at high risk to develop HCC, from those who have already progressed to HCC. The results also provide insights into the altered metabolism between HCC and HCV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.